Financial Performance - The company reported a profit attributable to shareholders of approximately 315 million RMB, representing a year-on-year increase of 30.1% [1] - Total revenue reached approximately 558 million RMB, reflecting a year-on-year growth of 35.5% [1] - Gross profit was around 327 million RMB, with a year-on-year increase of 30.2% [1] - Basic earnings per share were 0.4323 RMB, and a final dividend of 0.1366 RMB per share was proposed [1] Business Solutions - The majority of the company's revenue comes from precision marketing solutions, which provide digital marketing services for pharmaceutical and medical device companies [2] - The number of clients for the precision marketing and enterprise solutions increased to 228 in 2024, a growth of 25.3% from 182 in 2023 [2] - The number of products covered by these solutions rose from 386 in 2023 to 506 in 2024, marking a year-on-year increase of 31.1% [2] - Revenue from precision marketing and enterprise solutions grew by 37.5% to 512.5 million RMB in 2024, up from 372.7 million RMB in 2023 [2] Medical Knowledge Solutions - Revenue from medical knowledge solutions increased by approximately 10.8% to 17.9 million RMB, driven by an expanded user base and more medical knowledge products [3] - The smart patient management solutions saw a revenue increase of about 21.0% to 28 million RMB, attributed to the effectiveness of the single-disease patient management platform [3]
医脉通(02192)公布2024年业绩 母公司拥有人应占溢利约3.15亿元 同比增长30.1%